ClinicalTrials.gg
CompletedNCT01592747Updated Apr 24, 2019Results posted

Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine

A Phase 2 interventional study of Memantine Hydrochloride (HCl) and Memantine Hydrochloride (HCl) in Autistic Disorder, Autism and Asperger's Disorder, sponsored by Forest Laboratories. Completed at 94 sites in 15 countries. Open to participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2019-04-24.

Sponsored by Forest Laboratories (part of AbbVie) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
479
Allocation
Randomized
Ages
6 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 603 studies in Autistic Disorder with a site in United States — 123 open to participants now, 152 under way, 3 of them phase 3. Autistic Disorder · United States.

Enrollment
13th of 504
479 · median 44
Started
2012
with 25 others
Phase 2
95 of 603
11 open now
Registered
187th of 603
by date

Among the 603 studies in Autistic Disorder with a site in United States, this one is the 13th largest by enrollment of the 504 interventional ones that give a count, is one of 26 that started in 2012, is one of 95 in phase 2, and was the 187th registered.

Autistic Disorder

1,033 studies on the registry are indexed under Autistic Disorder; 269 are open to participants now.

Browse Autistic Disorder studies →

Open to participants now

123 of the 603 studies in Autistic Disorder with a site in United States are open now. Recruiting first, the newest first:

118 more — sign in →

All 123 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 183 Autistic Disorder studies recruiting now, 33 (18%) set no upper age limit and 143 (78%) stop at 75 or younger; 148 take children under 18; 56 take healthy volunteers.

This study: 6 Years to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 603 studies in Autistic Disorder with a site in United States, or all of them as a file.
02

Study summary

The purpose of this randomized withdrawal study is to evaluate the safety, tolerability, and efficacy of memantine compared with placebo in pediatric patients with autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS).

Read the detailed description

This clinical study was a 12-week, multicenter, double-blind, placebo-controlled, randomized withdrawal study in pediatric outpatients with autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS). Patients who completed at least 12 weeks of study drug exposure and met protocol specified responder criterion in lead in Study MEM-MD-91 (NCT01592786) at two consecutive visits separated by at least two weeks were eligible to transition to this study. The responder criterion was defined as having at least a 10 point improvement (reduction in score) in the Social Responsiveness Scale (SRS) total raw score relative to the Visit 1 total raw score in Study MEM-MD-91.

Weight based dose limits were selected in this study to ensure that exposure in terms of area under the curve (AUC) was less than the predefined limit of 2100 ng·h/mL which represents a 10-fold lower exposure than observed at the NOAEL(No observed adverse effect level) of 15 mg/kg/day in juvenile rats.

The weight-based dose limits in this study were as follows:

  • Group A: ≥ 60 kg; maximum 15 mg/day
  • Group B: 40-59 kg; maximum 9 mg/day
  • Group C: 20-39 kg; maximum 6 mg/day
  • Group D: \< 20 kg; maximum 3 mg/day
03

Conditions studied

  • Autistic Disorder
  • Autism
  • Asperger's Disorder
  • Asperger Syndrome
  • Autism Spectrum Disorders
  • Pervasive Developmental Disorder - Not Otherwise Specified (PDD-NOS)

Keywords

  • Asperger's
  • Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
  • Memantine
  • Pediatric Disorder
  • Randomized Controlled Trial
04

Who can participate

Ages eligible
6 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Completed at least 12 weeks of exposure to study drug in lead-in study MEM-MD-91 (NCT01592786)
  2. Met responder criterion at two consecutive visits separated by at least two weeks in lead-in study MEM-MD-91
  3. Provide written informed assent, when developmentally appropriate, to participate in the study before conduct of any study-specific procedures. The parent/guardian/LAR must provide written before the patient's participation in the study. A separate written informed consent for the caregiver must also be obtained before the conduct of any study specific procedures
  4. Have a knowledgeable caregiver who is capable of providing reliable information about the patient's condition, attending all clinic visits with the patient, and overseeing the administration of study drug. Every effort should be made to maintain the same caregiver as used in the lead-in study throughout this study
  5. Have normal results from the physical examination, laboratory tests, , and vital signs at Visit 1 of this study (last visit of Study MEM-MD-91). Any abnormal findings must be deemed not by the Investigator and documented
  6. Be able to speak and understand English sufficiently (or their native language if this can be accommodated by the site), as well as have a caregiver and parent/guardian/LAR who is able to speak and understand English sufficiently (or their native language if this can be accommodated by the site), to comprehend the nature of the study and to allow for the completion of all study assessments
  7. Have a family that is sufficiently organized and stable to guarantee adequate safety monitoring and continuous attendance to clinic visits for the duration of the study
  8. Females who are 9 years and older or who have had onset of menses must have a negative urine pregnancy test at Visit 1
  9. Age of 6 years to 12 years at the time of entry into lead in study MEM-MD-91

Exclusion criteria

Exclusion Criteria:

  1. Patients with a concurrent medical condition that might interfere with the conduct of the study, confound interpretation of the study results, or endanger the patient's well being
  2. Significant risk of suicidality based on the Investigator's judgment, the Aberrant Behavior Checklist-Irritability subscale (ABC-I), or if appropriate, as indicated by a response of "yes" to questions 4 or 5 in the suicidal ideation section of the Children's C-SSRS (Columbia-Suicide Severity Rating Scale) or any suicidal behavior.
  3. Patients with evidence or history of (other than excised basal cell carcinoma) or any significant hematologic, endocrine, cardiovascular (including any rhythm disorder), neurologic, respiratory, renal, hepatic, or gastrointestinal disease
  4. Female patients of who are not using or not willing to use a conventional method of approved by the PI. Abstinence is an acceptable method of contraception
  5. Patients requiring treatment with prohibited concomitant medications
  6. Patients who, in the opinion of the Investigator, might not be suitable for the study
  7. Employee or immediate relative of an employee of Forest Laboratories, Inc., any of its affiliates or partners, or the study center
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
479 participants (actual)

Study arms

  • Experimental
    Memantine 1

    Patients randomized to the full dose arm will continue taking memantine at the same tolerability and weight-based dose achieved in lead-in Study MEM-MD-91. Dosing will be once daily for up to 12 weeks.

    Drug: Memantine Hydrochloride (HCl)

  • Experimental
    Memantine 2

    Patients randomized to the reduced dose arm will take memantine at the tolerability and weight based dose that they received in lead in Study MEM-MD-91 reduced by at least 50%. Dosing will be once daily for up to 12 weeks.

    Drug: Memantine Hydrochloride (HCl)

  • Placebo comparator
    Placebo

    Dosing will be once daily for up to 12 weeks.

    Drug: Placebo capsules

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of Patients Meeting the Criterion for Loss of Therapeutic Response (LTR) by the End of the Study (Based on Observed Cases)

    Loss of Therapeutic response is defined as a worsening (increase) of at least 10 points in Social Responsiveness Scale (SRS) total raw score relative to the Visit 1 (randomization) score. The Social Responsiveness Scale (SRS) is a 65-item informant-rated assessment with total raw score ranging from 0 (no impairment) to 195 (severe social impairment). Each item is associated with 1 of 5 subscales (social awareness, social cognition, social communication, social motivation and autistic mannerisms). Each item is rated on a 4-point scale from 1 (not true) to 4 (almost always true). The scores are then transposed to a scale from 0 to 3 and scores are summed within each of the 5 subscales. A higher score indicates greater severity of social impairment.

    Time frame: Baseline (Visit 1) to week 12

Secondary outcomes

  1. Time to First Loss of Therapeutic (LTR) Response

    Time to the first visit when a patient shows LTR following randomization to memantine or placebo.

    Time frame: Baseline to week 12

  2. Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Speech Subscale at Week 12

    The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Speech Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times \[more than twice\] a day or always), with a total raw score of 0 (mildest) to 21 (most severe).

    Time frame: Baseline (Visit 1) to week 12

  3. Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Syntax Subscale at Week 12

    The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Syntax Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times \[more than twice\] a day or always), with a total raw score of 0 (mildest) to 21 (most severe).

    Time frame: Baseline (Visit 1) to week 12

  4. Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Semantics Subscale at Week 12

    The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Semantics Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times \[more than twice\] a day or always), with a total raw score of 0 (mildest) to 21 (most severe).

    Time frame: Baseline (Visit 1) to week 12

  5. Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Coherence Subscale at Week 12

    The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Coherence Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times \[more than twice\] a day or always), with a total raw score of 0 (mildest) to 21 (most severe).

    Time frame: Baseline (Visit 1) to week 12

  6. Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Initiation Subscale at Week 12

    The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Initiation Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times \[more than twice\] a day or always), with a total raw score of 0 (mildest) to 21 (most severe).

    Time frame: Baseline (Visit 1) to week 12

  7. Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Scripted Language Subscale at Week 12

    The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Scripted language Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times \[more than twice\] a day or always), with a total raw score of 0 (mildest) to 21 (most severe).

    Time frame: Baseline (Visit 1) to week 12

  8. Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Context Subscale at Week 12

    The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Context Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times \[more than twice\] a day or always), with a total raw score of 0 (mildest) to 21 (most severe).

    Time frame: Baseline (Visit 1) to week 12

  9. Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Nonverbal Communication Subscale at Week 12

    The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Nonverbal communication Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times \[more than twice\] a day or always), with a total raw score of 0 (mildest) to 21 (most severe).

    Time frame: Baseline (Visit 1) to week 12

  10. Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Social Relations Subscale at Week 12

    The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Social Relations Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times \[more than twice\] a day or always), with a total raw score of 0 (mildest) to 21 (most severe).

    Time frame: Baseline (Visit 1) to week 12

  11. Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Interests Subscale at Week 12

    The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Interests Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times \[more than twice\] a day or always), with a total raw score of 0 (mildest) to 21 (most severe).

    Time frame: Baseline (Visit 1) to week 12

07

Results

Posted Apr 24, 2019

Participant flow

Patient recruitment occurred over a ten month period, from September of 2012 to June of 2013, at 92 study sites, located in the Untied States and 14 other countries.

Participant flow — Overall Study
MilestonePlaceboMemantine Reduced DoseMemantine Full-Dose
Started160161158
Completed445050
Not completed116111108
Withdrew: Loss of therapeutic response107108100
Withdrew: Inclusion/exclusion criteria not met011
Withdrew: Adverse event100
Withdrew: Protocol violation404
Withdrew: Lack of efficacy010
Withdrew: Withdrawal by subject202
Withdrew: Lost to follow-up101
Withdrew: Other reasons110

Outcome measures

PrimaryProportion of Patients Meeting the Criterion for Loss of Therapeutic Response (LTR) by the End of the Study (Based on Observed Cases)

Loss of Therapeutic response is defined as a worsening (increase) of at least 10 points in Social Responsiveness Scale (SRS) total raw score relative to the Visit 1 (randomization) score. The Social Responsiveness Scale (SRS) is a 65-item informant-rated assessment with total raw score ranging from 0 (no impairment) to 195 (severe social impairment). Each item is associated with 1 of 5 subscales (social awareness, social cognition, social communication, social motivation and autistic mannerisms). Each item is rated on a 4-point scale from 1 (not true) to 4 (almost always true). The scores are then transposed to a scale from 0 to 3 and scores are summed within each of the 5 subscales. A higher score indicates greater severity of social impairment.

Time frame:
Baseline (Visit 1) to week 12
Reported as:
Number · Percentage of patients with LTR
Proportion of Patients Meeting the Criterion for Loss of Therapeutic Response (LTR) by the End of the Study (Based on Observed Cases)
Percentage of patients with LTRPlaceboMemantine Reduced DoseMemantine Full-Dose
Proportion of Patients Meeting the Criterion for Loss of Therapeutic Response (LTR) by the End of the Study (Based on Observed Cases)69.067.566.7
Statistical analysis
  • Placebo vs Memantine Full-Dose · Cochran-Mantel-Haenszel · p = 0.6590 · Odds ratio (or): 1.1 · 95% CI 0.7 to 1.8
  • Placebo vs Memantine Reduced Dose · Cochran-Mantel-Haenszel · p = 0.7839 · Odds ratio (or): 1.1 · 95% CI 0.7 to 1.7
SecondaryTime to First Loss of Therapeutic (LTR) Response

Time to the first visit when a patient shows LTR following randomization to memantine or placebo.

Time frame:
Baseline to week 12
Reported as:
Median · Days
Time to First Loss of Therapeutic (LTR) Response
DaysPlaceboMemantine Reduced DoseMemantine Full-Dose
Time to First Loss of Therapeutic (LTR) Response29 (28 to 42)33 (28 to 56)30 (28 to 44)
SecondaryChange From Baseline in Children's Communication Checklist-2 (CCC-2) - Speech Subscale at Week 12

The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Speech Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times \[more than twice\] a day or always), with a total raw score of 0 (mildest) to 21 (most severe).

Time frame:
Baseline (Visit 1) to week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Speech Subscale at Week 12
units on a scalePlaceboMemantine Reduced DoseMemantine Full-Dose
Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Speech Subscale at Week 120.1 ± 0.20.1 ± 0.20.2 ± 0.2
Statistical analysis
  • Placebo vs Memantine Full-Dose · ANCOVA · p = 0.8136 · Least squares mean difference: 0.1 · 95% CI -0.5 to 0.7
  • Placebo vs Memantine Reduced Dose · ANCOVA · p = 0.9244 · Least squares mean difference: -0.0 · 95% CI -0.6 to 0.5
SecondaryChange From Baseline in Children's Communication Checklist-2 (CCC-2) - Syntax Subscale at Week 12

The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Syntax Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times \[more than twice\] a day or always), with a total raw score of 0 (mildest) to 21 (most severe).

Time frame:
Baseline (Visit 1) to week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Syntax Subscale at Week 12
units on a scalePlaceboMemantine Reduced DoseMemantine Full-Dose
Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Syntax Subscale at Week 120.0 ± 0.20.3 ± 0.20.1 ± 0.2
Statistical analysis
  • Placebo vs Memantine Full-Dose · ANCOVA · p = 0.7611 · Least squares mean difference: 0.1 · 95% CI -0.5 to 0.7
  • Placebo vs Memantine Reduced Dose · ANCOVA · p = 0.3176 · Least squares mean difference: 0.3 · 95% CI -0.3 to 0.9
SecondaryChange From Baseline in Children's Communication Checklist-2 (CCC-2) - Semantics Subscale at Week 12

The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Semantics Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times \[more than twice\] a day or always), with a total raw score of 0 (mildest) to 21 (most severe).

Time frame:
Baseline (Visit 1) to week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Semantics Subscale at Week 12
units on a scalePlaceboMemantine Reduced DoseMemantine Full-Dose
Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Semantics Subscale at Week 120.3 ± 0.20.7 ± 0.20.3 ± 0.2
Statistical analysis
  • Placebo vs Memantine Full-Dose · ANCOVA · p = 0.9020 · Least squares mean difference: 0.0 · 95% CI -0.5 to 0.6
  • Placebo vs Memantine Reduced Dose · ANCOVA · p = 0.1279 · Least squares mean difference: 0.4 · 95% CI -0.1 to 1.0
SecondaryChange From Baseline in Children's Communication Checklist-2 (CCC-2) - Coherence Subscale at Week 12

The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Coherence Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times \[more than twice\] a day or always), with a total raw score of 0 (mildest) to 21 (most severe).

Time frame:
Baseline (Visit 1) to week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Coherence Subscale at Week 12
units on a scalePlaceboMemantine Reduced DoseMemantine Full-Dose
Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Coherence Subscale at Week 120.7 ± 0.31.0 ± 0.31.0 ± 0.3
Statistical analysis
  • Placebo vs Memantine Full-Dose · ANCOVA · p = 0.4144 · Least squares mean difference: 0.3 · 95% CI -0.4 to 1.1
  • Placebo vs Memantine Reduced Dose · ANCOVA · p = 0.4212 · Least squares mean difference: 0.3 · 95% CI -0.4 to 1.0
SecondaryChange From Baseline in Children's Communication Checklist-2 (CCC-2) - Initiation Subscale at Week 12

The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Initiation Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times \[more than twice\] a day or always), with a total raw score of 0 (mildest) to 21 (most severe).

Time frame:
Baseline (Visit 1) to week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Initiation Subscale at Week 12
units on a scalePlaceboMemantine Reduced DoseMemantine Full-Dose
Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Initiation Subscale at Week 121.4 ± 0.31.6 ± 0.31.2 ± 0.3
Statistical analysis
  • Placebo vs Memantine Full-Dose · ANCOVA · p = 0.6238 · Least squares mean difference: -0.2 · 95% CI -0.9 to 0.5
  • Placebo vs Memantine Reduced Dose · ANCOVA · p = 0.5957 · Least squares mean difference: 0.2 · 95% CI -0.5 to 0.9
SecondaryChange From Baseline in Children's Communication Checklist-2 (CCC-2) - Scripted Language Subscale at Week 12

The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Scripted language Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times \[more than twice\] a day or always), with a total raw score of 0 (mildest) to 21 (most severe).

Time frame:
Baseline (Visit 1) to week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Scripted Language Subscale at Week 12
units on a scalePlaceboMemantine Reduced DoseMemantine Full-Dose
Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Scripted Language Subscale at Week 120.8 ± 0.21.1 ± 0.20.9 ± 0.2
Statistical analysis
  • Placebo vs Memantine Full-Dose · ANCOVA · p = 0.8640 · Least squares mean difference: 0.1 · 95% CI -0.6 to 0.7
  • Placebo vs Memantine Reduced Dose · ANCOVA · p = 0.4362 · Least squares mean difference: 0.3 · 95% CI -0.4 to 0.9
SecondaryChange From Baseline in Children's Communication Checklist-2 (CCC-2) - Context Subscale at Week 12

The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Context Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times \[more than twice\] a day or always), with a total raw score of 0 (mildest) to 21 (most severe).

Time frame:
Baseline (Visit 1) to week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Context Subscale at Week 12
units on a scalePlaceboMemantine Reduced DoseMemantine Full-Dose
Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Context Subscale at Week 120.9 ± 0.30.8 ± 0.30.8 ± 0.3
Statistical analysis
  • Placebo vs Memantine Full-Dose · ANCOVA · p = 0.7182 · Least squares mean difference: -0.1 · 95% CI -0.8 to 0.6
  • Placebo vs Memantine Reduced Dose · ANCOVA · p = 0.8390 · Least squares mean difference: -0.1 · 95% CI -0.8 to 0.6
SecondaryChange From Baseline in Children's Communication Checklist-2 (CCC-2) - Nonverbal Communication Subscale at Week 12

The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Nonverbal communication Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times \[more than twice\] a day or always), with a total raw score of 0 (mildest) to 21 (most severe).

Time frame:
Baseline (Visit 1) to week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Nonverbal Communication Subscale at Week 12
units on a scalePlaceboMemantine Reduced DoseMemantine Full-Dose
Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Nonverbal Communication Subscale at Week 121.2 ± 0.31.5 ± 0.31.8 ± 0.3
Statistical analysis
  • Placebo vs Memantine Full-Dose · ANCOVA · p = 0.0813 · Least squares mean difference: 0.7 · 95% CI -0.1 to 1.4
  • Placebo vs Memantine Reduced Dose · ANCOVA · p = 0.4365 · Least squares mean difference: 0.3 · 95% CI -0.4 to 1.0
SecondaryChange From Baseline in Children's Communication Checklist-2 (CCC-2) - Social Relations Subscale at Week 12

The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Social Relations Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times \[more than twice\] a day or always), with a total raw score of 0 (mildest) to 21 (most severe).

Time frame:
Baseline (Visit 1) to week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Social Relations Subscale at Week 12
units on a scalePlaceboMemantine Reduced DoseMemantine Full-Dose
Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Social Relations Subscale at Week 121.5 ± 0.31.8 ± 0.31.8 ± 0.3
Statistical analysis
  • Placebo vs Memantine Full-Dose · ANCOVA · p = 0.4213 · Least squares mean difference: 0.3 · 95% CI -0.4 to 1.0
  • Placebo vs Memantine Reduced Dose · ANCOVA · p = 0.4267 · Least squares mean difference: 0.3 · 95% CI -0.4 to 1.0
SecondaryChange From Baseline in Children's Communication Checklist-2 (CCC-2) - Interests Subscale at Week 12

The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Interests Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times \[more than twice\] a day or always), with a total raw score of 0 (mildest) to 21 (most severe).

Time frame:
Baseline (Visit 1) to week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Interests Subscale at Week 12
units on a scalePlaceboMemantine Reduced DoseMemantine Full-Dose
Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Interests Subscale at Week 120.9 ± 0.31.3 ± 0.31.2 ± 0.3
Statistical analysis
  • Placebo vs Memantine Full-Dose · ANCOVA · p = 0.3713 · Least squares mean difference: 0.3 · 95% CI -0.4 to 1.0
  • Placebo vs Memantine Reduced Dose · ANCOVA · p = 0.2855 · Least squares mean difference: 0.4 · 95% CI -0.3 to 1.1

Adverse events

Collected over Adverse events were collected for a 14 month period from September of 2012 to October of 2013 at 92 study centers in the United States and 14 other countries.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/160 (0%)8/160 (5%)
Memantine Reduced Dose—1/160 (0.6%)5/160 (3.1%)
Memantine Full-Dose—0/157 (0%)4/157 (2.5%)
Most frequent serious events
Most frequent serious events
EventPlaceboMemantine Reduced DoseMemantine Full-Dose
FuruncleInfections and infestations0/1601/1600/157
Most frequent other events
Most frequent other events
EventPlaceboMemantine Reduced DoseMemantine Full-Dose
IrritabilityGeneral disorders8/1605/1604/157

Baseline characteristics

479 patients were screened and randomized. Of these, 477 patients received at least 1 dose of double-blind investigational product (Safety Population). The baseline characteristics presented here are for the Safety population.

Age, Continuous
Age, Continuous(years)PlaceboMemantine Reduced DoseMemantine Full-DoseTotal
Mean8.9 ± 2.09.2 ± 1.99.2 ± 1.99.1 ± 1.9
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboMemantine Reduced DoseMemantine Full-DoseTotal
Female18282571
Male142132132406
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboMemantine Reduced DoseMemantine Full-DoseTotal
Hispanic or Latino23221560
Not Hispanic or Latino137138142417
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboMemantine Reduced DoseMemantine Full-DoseTotal
White138141140419
Black or African American109726
Asian75820
American Indian or Alaska Native0101
Native Hawaiian or Other Pacific Islander1102
Other4329
Region of Enrollment
Region of Enrollment(Participants)PlaceboMemantine Reduced DoseMemantine Full-DoseTotal
United States134125126385
Belgium2114
Colombia1225
Estonia0101
France1427
Hungary3328
Iceland0303
Italy2114
Korea, Republic of63514
New Zealand0112
Poland561021
Serbia36514
South Africa0011
Spain1012
Ukraine2406
Autism Spectrum Disorder Subtype
Autism Spectrum Disorder Subtype(Participants)PlaceboMemantine Reduced DoseMemantine Full-DoseTotal
Autism10199100300
Asperger's Disorder30302787
PDD-NOS29313090
08

Study locations

94 sites
  • Forest Investigative Site 068
    Dothan, Alabama 36303, United States
  • Forest Investigative Site 005
    Phoenix, Arizona 85006, United States
  • Forest Investigative Site 055
    Tucson, Arizona 85718, United States
  • Forest Investigative Site 077
    Little Rock, Arkansas 72202-3591, United States
  • Forest Investigative Site 054
    Glendale, California 91206, United States
  • Forest Investigative Site 109
    Imperial, California 92251, United States
  • Forest Investigative Site 096
    Los Angeles, California 90024, United States
  • Forest Investigative Site 021
    San Francisco, California 94143-0984, United States
  • Forest Investigative Site 026
    Santa Ana, California 92701, United States
  • Forest Investigative Site 002
    Stanford, California 94305-5719, United States
  • Forest Investigative Site 078
    Boulder, Colorado 80304, United States
  • Forest Investigative Site 073
    Centennial, Colorado 80112, United States
  • Forest Investigative Site 052
    Washington, District of Columbia 20010-2970, United States
  • Forest Investigative Site 075
    Bradenton, Florida 32751, United States
  • Forest Investigative Site 080
    Gainesville, Florida 32607, United States
  • Forest Investigative Site 117
    Jacksonville, Florida 32216, United States
  • Forest Investigative Site 065
    Maitland, Florida 32751, United States
  • Forest Investigative Site 118
    Miami, Florida 33155, United States
  • Forest Investigative Site 085
    Oakland Park, Florida 33334, United States
  • Forest Investigative Site 115
    Orange City, Florida 32763, United States
  • Forest Investigative Site 125
    Orlando, Florida 32803, United States
  • Forest Investigative Site 062
    Orlando, Florida 32806, United States
  • Forest Investigative Site 067
    Tampa, Florida 33612, United States
  • Forest Investigative Site 101
    Wellington, Florida 33414, United States
  • Forest Investigative Site 102
    Libertyville, Illinois 60048, United States
  • Forest Investigative Site 023
    Naperville, Illinois 60563, United States
  • Forest Investigative Site 082
    Evansville, Indiana 47713, United States
  • Forest Investigative Site 056
    Indianapolis, Indiana 46260, United States
  • Forest Investigative Site 106
    Wichita, Kansas 67214-3199, United States
  • Forest Investigative Site 061
    Louisville, Kentucky 40202, United States
  • Forest Investigative Site 095
    Lake Charles, Louisiana 70605, United States
  • Forest Investigative Site 086
    Rockville, Maryland 20852, United States
  • Forest Investigative Site 059
    Newton, Massachusetts 02459, United States
  • Forest Investigative Site 108
    Springfield, Massachusetts 01199, United States
  • Forest Investigative Site 116
    Lincoln, Nebraska 68516, United States
  • Forest Investigative Site 097
    Lincoln, Nebraska 68526, United States
  • Forest Investigative Site 130
    Henderson, Nevada 89052, United States
  • Forest Investigative Site 104
    Las Vegas, Nevada 89128, United States
  • Forest Investigative Site 136
    Neptune, New Jersey 07753, United States
  • Forest Investigative Site 127
    Toms River, New Jersey 08755, United States
  • Forest Investigative Site 081
    Albuquerque, New Mexico 87108-5129, United States
  • Forest Investigative Site 107
    Albuquerque, New Mexico 87109, United States
  • Forest Investigative Site 072
    Chapel Hill, North Carolina 27514, United States
  • Forest Investigative Site 069
    Avon Lake, Ohio 44012, United States
  • Forest Investigative Site 001
    Columbus, Ohio 43210, United States
  • Forest Investigative Site 019
    Oklahoma City, Oklahoma 73116, United States
  • Forest Investigative Site 092
    Tulsa, Oklahoma 74104, United States
  • Forest Investigative Site 053
    Gresham, Oregon 97030, United States
  • Forest Investigative Site 132
    Johnstown, Pennsylvania 15904, United States
  • Forest Investigative Site 131
    McMurray, Pennsylvania 15317, United States
  • Forest Investigative Site 100
    Media, Pennsylvania 19063, United States
  • Forest Investigative Site 105
    Charleston, South Carolina 29407, United States
  • Forest Investigative Site 090
    Memphis, Tennessee 38119, United States
  • Forest Investigative Site 057
    Nashville, Tennessee 37232, United States
  • Forest Investigative Site 051
    Houston, Texas 77090, United States
  • Forest Investigative Site 070
    The Woodlands, Texas 77381, United States
  • Forest Investigative Site 028
    Clinton, Utah 84015, United States
  • Forest Investigative Site 141
    Ogden, Utah 84405, United States
  • Forest Investigative Site 029
    Salt Lake City, Utah 84106, United States
  • Forest Investigative Site 064
    Charlottesville, Virginia 22903, United States
  • Forest Investigative Site 113
    Norfolk, Virginia 23507, United States
  • Forest Investigative Site 071
    Bothell, Washington 98011, United States
  • Forest Investigative Site 119
    Charleston, West Virginia 25304, United States
  • Forest Investigative Site 063
    Middleton, Wisconsin 53562, United States
  • Forest Investigative Site 204
    Brussel, 1020, Belgium
  • Forest Investigative Site 203
    Bruxelles, 1090, Belgium
  • Forest Investigative Site 228
    Bello, Colombia
  • Forest Investigative Site 226
    Bogotá, Colombia
  • Forest Investigative Site 276
    Tallinn, 10617, Estonia
  • Forest Investigative Site 329
    Bron Cedex, 69677, France
  • Forest Investigative Site 381
    Budapest, 1026, Hungary
  • Forest Investigative Site 376
    Budapest, 1083, Hungary
  • Forest Investigative Site 378
    Budapest, 1089, Hungary
  • Forest Investigative Site 401
    Kopavogur, 200, Iceland
  • Forest Investigative Site 453
    Roma, 165, Italy
  • Forest Investigative Site 452
    Siena, 53100, Italy
  • Forest Investigative Site 704
    Yangsan-si, Gyeongsangnam-do 626-770, Korea, Republic of
  • Forest Investigative Site 702
    Seoul, 110744, Korea, Republic of
  • Forest Investigative Site 703
    Seoul, 120-752, Korea, Republic of
  • Forest Investigative Site 701
    Seoul, 138-736, Korea, Republic of
  • Forest Investigative Site 526
    Wellington, 6012, New Zealand
  • Forest Investigative Site 579
    Gdansk, 80-542, Poland
  • Forest Investigative Site 578
    Gdansk, 80-952, Poland
  • Forest Investigative Site 576
    Kobierzyce, 55-040, Poland
  • Forest Investigative Site 577
    Warszawa, 02-957, Poland
  • Forest Investigative Site 626
    Belgrade, 11000, Serbia
  • Forest Investigative Site 627
    Belgrade, 11000, Serbia
  • Forest Investigative Site 629
    Nis, 18000, Serbia
  • Forest Investigative Site 628
    Novi Sad, 21000, Serbia
  • Forest Investigative Site 676
    Cape Town, Western Cape 7530, South Africa
  • Forest Investigative Site 728
    Sabadell, Barcelona 8208, Spain
  • Forest Investigative Site 807
    Kharkiv, 61153, Ukraine
  • Forest Investigative Site 802
    Kherson,Vil. Stepanivka, 73488, Ukraine
  • Forest Investigative Site 804
    Kyiv, 04080, Ukraine
09

References and documents

Publications

  • Brignell A, Marraffa C, Williams K, May T. Memantine for autism spectrum disorder. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013845. doi: 10.1002/14651858.CD013845.pub2. PubMed 36006807 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2012, a primary completion of Sep 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2019, 5 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2012
First posted
May 7, 2012
Start
Sep 2012
Primary completionActual
Sep 2013
CompletionActual
Oct 2013
Results first posted
Apr 24, 2019
Last update
Apr 24, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01592747
Responsible party
Sponsor
First posted
May 7, 2012
Start date
Sep 2012
Primary completion
Sep 2013
Completion
Oct 2013
Results posted
Apr 24, 2019
Last update
Apr 24, 2019

Study contacts

Jordan Lateiner, MS, MBA
study director · Forest Research Institute, Inc.- A Subsidiary of Forest Laboratories, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Memantine

Start the discussion